The immune system plays a fundamental role in both the development and pathobiology of stroke. Inflammasomes are multiprotein complexes that have come to be recognized as critical players in the inflammation that ultimately contributes to stroke severity. Inflammasomes recognize microbial and host-derived danger signals and activate caspase-1， which in turn controls the production of the pro-inflammatory cytokine IL-1β. We have shown that A151， a synthetic oligodeoxynucleotide containing multiple telemeric TTAGGG motifs， reduces IL-1β production by activated bone marrow derived macrophages that have been subjected to oxygen-glucose deprivation and LPS stimulation. Further， we demonstrate that A151 red... More
The immune system plays a fundamental role in both the development and pathobiology of stroke. Inflammasomes are multiprotein complexes that have come to be recognized as critical players in the inflammation that ultimately contributes to stroke severity. Inflammasomes recognize microbial and host-derived danger signals and activate caspase-1， which in turn controls the production of the pro-inflammatory cytokine IL-1β. We have shown that A151， a synthetic oligodeoxynucleotide containing multiple telemeric TTAGGG motifs， reduces IL-1β production by activated bone marrow derived macrophages that have been subjected to oxygen-glucose deprivation and LPS stimulation. Further， we demonstrate that A151 reduces the maturation of caspase-1 and IL-1β， the levels of both the iNOS and NLRP3 proteins， and the depolarization of mitochondrial membrane potential within such cells. In addition， we have demonstrated that A151 reduces ischemic brain damage and NLRP3 mRNA levels in SHR-SP rats that have undergone permanent middle cerebral artery occlusion. These findings clearly suggest that the modulation of inflammasome activity via A151 may contribute to a reduction in pro-inflammatory cytokine production by macrophages subjected to conditions that model brain ischemia and modulate ischemic brain damage in an animal model of stroke. Therefore， modulation of ischemic pathobiology by A151 may have a role in the development of novel stroke prevention and therapeutic strategies.
